1YBetter than half the group
Rank 26 of 63 funds
Return +19.68%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 26No. 1 is SCBGENOME(E) +62.13%
KKP GLOBAL HEALTH CARE FUND
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
KKP GHC-D invests through the master fund Janus Henderson Global Life Sciences Fund 98.92%
This fundKKP GHC-D
The fund that actually investsJanus Henderson Global Life Sciences FundThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Eli Lilly and Co LLY9.51%
Johnson & Johnson JNJ7.70%Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per Janus Henderson fact sheet
Over the past year it beat half its group; over 5 years it returned +2.23% per year (Better than half the group)
No. 1 is SCBGENOME(E) +62.13%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | 7Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +9.75% | +2.42% | +2.52% | +7.27% | +4.66% | +13.85% | +19.68% | +36.81% | +11.66% | +64.37% | +97.84% |
Largest drawdown in the selected period −38.20% Previous peak 11 Aug 2008 (NAV 5.0875) → Trough 9 Mar 2009 (NAV 3.1442) · Back to the previous peak on 1 Apr 2011, after 2 years
Currently −2.42% from the peak NAV of 18.1352 (19 Aug 2026)
Over 5 years, KKP GHC-D returned 0.13 per unit of volatility, ranking 12 of 33 funds · The highest is FP HCARE-A (0.43)
Paid once in the past 12 months, totalling 1.7400 THB per unit, or 9.83% of NAV
KKP GHC-D pays cash dividends to unitholders from part of the fund's profit. Below is a summary of when you get paid, how much, and how regularly
THB/unit, totalled by year of payment · * 2026 to 3 Nov 2026
Based on NAV 16.4483 → 17.6965 THB (3 Nov 2025 – 3 Nov 2026) and dividends over the same period
Unitholders' total value doesn't disappear. Part of it moves from the NAV into cash (the example assumes asset prices don't change that day) · See the D markers on the NAV chart
รายละเอียดเพิ่มเติมเกี่ยวกับนโยบายการลงทุน กองทุนเป็นกองทุนรวมประเภท Feeder Fund ที่เน้นลงทุนในหน่วยลงทุนของกองทุนรวมหลักในต่างประเทศเพียงกองทุนเดียว คือ Janus Henderson Global Life Sciences Fund (“กองทุนหลัก”) ซึ่งลงทุนอย่างน้อยร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุนหลักในตราสารทุนของบริษัทต่าง… Its largest holdings are JHCF - JANUS HENDERSON GLOBAL LIFE SCIENCES FUND (JGLSUAU ID) 98.92% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 12 Mar 2008, its NAV has fallen as much as −38.20% from its peak.
Actual total expense ratio (TER) 1.21% a year, against a ceiling of 3.40%. Management fee 1.07%. Front-end fee 1.00%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
Yes. The latest was 1.7400 THB per unit, book close 19 May 2026, paid 29 May 2026 · 15 payments so far, totalling 12.6250 THB per unit. Dividends are subject to 10% withholding tax and are not guaranteed
Minimum first purchase 1,000 THB, subsequent purchases 1,000 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+4
Hedged at the manager's discretion. As of 30 Sep 2026, 100.27% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · KKP GHC-D: pays dividends, TER 1.21% · KKP GHC-A: no dividends, TER 1.21% · KKP GHC-E: see the conditions in the prospectus · KKP GHC-ES: see the conditions in the prospectus · KKP GHC-F: see the conditions in the prospectus · KKP GHC-M: see the conditions in the prospectus
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Unitedhealth Group UNH4.22%
AstraZeneca AZN.L3.67%
Thermo Fisher TMO3.31%
Novartis NOVN2.70%
Roche ROG2.65%
argenx ARGX2.42%
Merck & MRK2.32%Eli Lilly and Co LLYDiabetes and weight-loss drugs
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
ABBVIE ABBVHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
AstraZeneca AZN.LHospitals, medicines and medical equipment
Thermo Fisher TMOAn American company selling scientific instruments, reagents and services for laboratories
Novartis NOVNHospitals, medicines and medical equipment
Roche ROGHospitals, medicines and medical equipment
argenx ARGXEuropean biotech that makes Vyvgart to treat autoimmune diseases such as myasthenia gravis
Merck & MRKHospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (98.92% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from Janus Henderson · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +21.97% per year
No. 1 is FP HCARE-A +6.61% per year
| +289.79% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.1 | +1.7 | −6.6 | +1.3 | +1.7 | +7.8 | −0.8 | +3.3 | −4.4 | +6.4 | −0.5 | · | +9.8* |
| 2025 | +5.4 | −0.4 | −6.3 | −2.0 | −8.2 | +1.8 | −1.2 | +5.7 | +2.3 | +8.3 | +9.2 | −0.6 | +13.2 |
| 2024 | +2.2 | +3.4 | +2.4 | −3.3 | +0.1 | +2.9 | +0.5 | +4.2 | −3.2 | −1.3 | +1.6 | −9.6 | −0.8 |
| 2023 | −0.2 | −4.4 | +1.9 | +3.6 | −2.8 | +2.6 | +0.4 | −1.8 | −4.1 | −6.8 | +6.6 | +6.9 | +0.9 |
| 2022 | −9.3 | +0.3 | +3.5 | −6.9 | −1.2 | −1.0 | +4.0 | −3.5 | −3.2 | +7.7 | +4.9 | −1.4 | −7.2 |
THB/unit by book-close date
15 payments in total · 19 Jun 2008 – 29 May 2026
0 of 15 book-close dates match the SEC dividend history · The rest are inferred from the dates NAV fell by the dividend amount